ArticleJournal of surgical oncology2014
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Article in Journal of surgical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Comparison of overall survival across treatment modalities for oesophageal, gastroesophageal, and gastric cancer: protocol for a systematic review and network meta-analysis.Systematic reviews · 2026Pooled it
- Nomogram for predicting the likelihood of liver metastases at initial diagnosis in patients with Siewert type II gastroesophageal junction adenocarcinoma.Scientific reports · 2023Trial
- Trial
- Open Versus Hybrid and Total Minimally Invasive Transthoracic Ivor Lewis Esophagectomy Following Neoadjuvant FLOT Chemotherapy: An Australian and New Zealand Cohort Study.World journal of surgery · 2026Article
- Rethinking the Siewert classification in the era of precision oncology.Translational gastroenterology and hepatology · 2026Article
- Review
- Observational
- The Impact of Diagnostic Laparoscopy on Upstaging Patients with Siewert II and III Gastroesophageal Junction (GEJ) Cancer.Annals of surgical oncology · 2025Observational
- Time to Discard the Staging Laparoscopy? Elucidating the Role for Routine Diagnostic Laparoscopy in Patients with Gastroesophageal Junction Malignancy.Annals of surgical oncology · 2025Article
- Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.The British journal of surgery · 2022Article
- Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation.Cancers · 2022Review
- Research on the Histological Features and Pathological Types of Gastric Adenocarcinoma With Mucinous Differentiation.Frontiers in medicine · 2022Article
- Clinical characteristics and prediction model of long time survival of patients with stage M1 Siewert type II esophagogastric junction adenocarcinoma.Translational cancer research · 2021Article
- Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study.Annals of gastroenterological surgery · 2021Review
- Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study.Cancer causes & control : CCC · 2020Article
- Tissue classification of oncologic esophageal resectates based on hyperspectral data.International journal of computer assisted radiology and surgery · 2019Article
- The optimal extent of lymph node dissection in gastroesophageal junctional cancer: retrospective case control study.BMC cancer · 2019Article
- Updates on Management of Gastric Cancer.Current oncology reports · 2019Review
- Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study.Oncotarget · 2018Article
- Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.World journal of gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
introductionThe Siewert classification has been used to plan treatment for tumours of the gastro-oesophageal junction since its proposal in the 1980s. The purpose of this study was to assess its continued relevance by evaluating whether there were differences in the biology and clinical characteristics of adenocarcinomas by Siewert type, in a contemporary cohort of patients, in whom the majority had received neoadjuvant chemotherapy.
methodsA prospective database was reviewed for all patients who underwent resection from 2005 to 2011 and analysed with regard to Siewert classification determined from the pathological specimen, treatment and clinicopathological outcomes.
resultsTwo hundred and sixteen patients underwent oesophagogastric resection: 133 for type I, 51 for type II and 33 for type III tumours. 135 Patients (62.5%) received neoadjuvant chemotherapy with no difference between groups. There were no significant differences in age, sex, pT stage, pN stage, pM stage, ASA, or inpatient complications between patients with adenocarcinoma based on their Siewert classification. There was a significant increase in maximum tumour diameter (P = 0.023), perineural invasion (P = 0.021) and vascular invasion (P = 0.020), associated with more distal tumours (Type III > Type II > Type I). Median overall survival was significantly shorter for more distal tumours (Type I: 4.96 years vs. Type II: 3.3 years vs. Type III: 2.64 years; P = 0.04). The surgical approach did not influence survival.
conclusionIn the era of multi-modal treatment pathological Siewert tumour type is of prognostic value, as patients with Type III disease are likely to have larger and more aggressive tumours that lead to worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.